Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NIDA plans to fund research developing interventions to prevent and treat substance use disorders and overdoses, from preclinical studies to clinical trials.
Funder: National Institutes of Health (NIH)
Due Dates: October 20, 2025 | February 20, 2026 | June 22, 2026 | October 20, 2026 | February 22, 2027 | June 21, 2027 | October 20, 2027 | February 22, 2028 | June 20, 2028
Funding Amounts: Up to $3,000,000 direct costs/year; maximum project period is 5 years (UG3: up to 2 years, UH3: up to 3 years).
Summary: Supports preclinical and clinical research to discover and develop interventions (medications, devices, digital therapeutics, behavioral treatments) to prevent or treat substance use disorders and overdose.
Key Information: UG3/UH3 phased award; clear milestones required for transition; clinical trial optional.
Description
This funding opportunity supports research on the development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including co-morbid SUDs. The National Institute on Drug Abuse (NIDA) seeks applications for preclinical and clinical studies that can rapidly advance candidate interventions (such as medications, devices, digital therapeutics, and behavioral treatments) toward regulatory approval or clinical adoption. The mechanism is a phased UG3/UH3 cooperative agreement, requiring clear, quantitative milestones for transition between phases.
Research can address prevention of SUD initiation, progression, treatment adherence, withdrawal management, overdose prevention, and related outcomes. Projects may focus on pharmacotherapies, device-based treatments, digital therapeutics, or behavioral interventions (NIH Stage Model Stages I-III only).
